Matches in Wikidata for { <http://www.wikidata.org/entity/Q86255274> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q86255274 description "clinical trial" @default.
- Q86255274 description "ensayu clínicu" @default.
- Q86255274 description "klinisch onderzoek" @default.
- Q86255274 description "клінічне випробування" @default.
- Q86255274 name "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation" @default.
- Q86255274 name "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation" @default.
- Q86255274 type Item @default.
- Q86255274 label "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation" @default.
- Q86255274 label "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation" @default.
- Q86255274 prefLabel "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation" @default.
- Q86255274 prefLabel "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation" @default.
- Q86255274 P1132 Q86255274-3F18972E-A452-4C82-942D-E090EF656687 @default.
- Q86255274 P1476 Q86255274-27D7885B-E90B-455B-9D05-EC9318A62D82 @default.
- Q86255274 P1813 Q86255274-6497640A-101D-4AAB-92B8-32ED319254C8 @default.
- Q86255274 P2899 Q86255274-3D975D1D-0340-4CA4-BCD7-DBE2CF1CDE0E @default.
- Q86255274 P3098 Q86255274-4628BBB4-040C-43A1-80C3-F66D0F997E3D @default.
- Q86255274 P31 Q86255274-5FB60140-4715-4494-94C9-AC40A513210D @default.
- Q86255274 P4844 Q86255274-D3496E85-12DF-43BB-934C-C84F8EC09B11 @default.
- Q86255274 P580 Q86255274-EBEC12DB-2F59-4293-B463-F6F0C9B3FE64 @default.
- Q86255274 P582 Q86255274-F4A0139F-6DB1-4AC1-BDFE-74CD41223E00 @default.
- Q86255274 P6099 Q86255274-B622EE3B-E559-4C35-9EEC-521CFCBFFB9A @default.
- Q86255274 P8363 Q86255274-09B64587-A1EE-40A5-9FBE-ECBEF79A6032 @default.
- Q86255274 P859 Q86255274-F26B6C4B-66EF-4D4B-9DB6-1467116D8E41 @default.
- Q86255274 P921 Q86255274-40B16E71-175A-4B6A-895D-4F57CA147D7E @default.
- Q86255274 P921 Q86255274-8528C70B-8280-4E9E-A156-97142AFC5023 @default.
- Q86255274 P1132 "+566" @default.
- Q86255274 P1476 "A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation" @default.
- Q86255274 P1813 "EPIK-B3" @default.
- Q86255274 P2899 "+18" @default.
- Q86255274 P3098 "NCT04251533" @default.
- Q86255274 P31 Q30612 @default.
- Q86255274 P4844 Q423762 @default.
- Q86255274 P580 "2020-04-22T00:00:00Z" @default.
- Q86255274 P582 "2024-03-19T00:00:00Z" @default.
- Q86255274 P6099 Q42824827 @default.
- Q86255274 P8363 Q78089383 @default.
- Q86255274 P859 Q507154 @default.
- Q86255274 P921 Q27074391 @default.
- Q86255274 P921 Q28444976 @default.